Journal of Molecular Biology
Regular articleA Fast Flexible Docking Method using an Incremental Construction Algorithm
Abstract
We present an automatic method for docking organic ligands into protein binding sites. The method can be used in the design process of specific protein ligands. It combines an appropriate model of the physico-chemical properties of the docked molecules with efficient methods for sampling the conformational space of the ligand. If the ligand is flexible, it can adopt a large variety of different conformations. Each such minimum in conformational space presents a potential candidate for the conformation of the ligand in the complexed state. Our docking method samples the conformation space of the ligand on the basis of a discrete model and uses a tree-search technique for placing the ligand incrementally into the active site. For placing the first fragment of the ligand into the protein, we use hashing techniques adapted from computer vision. The incremental construction algorithm is based on a greedy strategy combined with efficient methods for overlap detection and for the search of new interactions. We present results on 19 complexes of which the binding geometry has been crystallographically determined. All considered ligands are docked in at most three minutes on a current workstation. The experimentally observed binding mode of the ligand is reproduced with 0.5 to 1.2 Å rms deviation. It is almost always found among the highest-ranking conformations computed.
References (0)
Cited by (2492)
In silico approach to design new cyclooxygenase-2 (COX-2) inhibitors based on MM/QM and ADMET analysis
2024, Chemical Physics ImpactIn spite of the availability of inhibitors targeting the Cyclooxygenase-2 (COX-2) enzyme, there persists a need for current medications, not solely within the realm of non-steroidal anti-inflammatory drugs (NSAIDs) but also in diverse therapeutic domains such as cancer prevention and Alzheimer's disease treatment. Amidst the COVID-19 pandemic in 2019, COX-2 selective inhibitors emerged as highly sought-after NSAIDs due to their efficacy in pain alleviation and prevention of inflammatory conditions. With an in-silico approach {amalgamation of Quantum Mechanics (QM) and Molecular Mechanics (MM)}. we evaluated a series of 70 new and potential anti-inflammatory compounds based upon the derivatives of arylhydrazone, pyrrolo [3,4-d] pyridazinone, 1,5-diphenyl pyrazole, and 2-imidazoline that interact with the COX-2 receptor (PDB ID: 1CX2) via molecular docking. 14 top-ranked compounds comparable to a standard drug (SC-58) were selected for drug-likeness properties such as physicochemical and ADMET. Subsequently, a selection of 12 highly promising molecules was made, and the target prediction tool effectively identified protein targets for the COX-2 compound. Following this, FMO (Frontier Molecular Orbital) and MEP (Molecular Electrostatic Potential) studies were conducted, revealing increased stability in the drug complexes due to a larger HOMO-LUMO gap. Additionally, a noteworthy electrophilicity index indicated favorable electrophilic behavior. The study also highlighted new advantageous binding sites for these 12 analogues, suggesting their importance as potential candidates for non-steroidal anti-inflammatory drugs in the treatment of inflammatory diseases.
Unveiling novel therapeutic avenues: Targeting the cyclin D/CDK4 axis for enhanced cancer treatment
2024, Medical HypothesesThe deregulation of the cyclin D/CDK complex is a prevalent feature in various cancer types, including colorectal cancer, breast cancer, and melanoma, leading to uncontrolled cell cycle progression and tumor growth. Targeting the cyclin D/CDK complex has emerged as a promising therapeutic strategy for cancer treatment. CDK4 inhibitors, such as ribociclib, palbociclib, and abemaciclib, have demonstrated clinical efficacy by disrupting the interaction between cyclin D and CDK4, essential for Retinoblastoma protein (pRb) phosphorylation and cell cycle progression. However, developing resistance to CDK4 inhibitors underscores the need for more potent alternatives. This hypothesizes that targeting the cyclin D/CDK axis can unveil novel therapeutic options surpassing the limitations of current cancer treatments. Conventional approaches like chemotherapy, radiation therapy, and CDK inhibitors exhibit efficacy but often have adverse side effects. By focusing on the cyclin D/CDK axis, this hypothesis aims to identify innovative strategies that offer greater selectivity, potency, and reduced side effects. Understanding the molecular mechanisms underlying cyclin D/CDK dysregulation in cancer is pivotal in advancing oncology therapeutics. The solution involves structural mining, molecular dynamics (MD) simulations, and in silico screening of compounds against the cyclin D/CDK axis. Initial MD simulations examine the binding mechanism of palbociclib, a known CDK4 inhibitor while docking studies screen diverse compound libraries to identify potential therapeutics. The outcomes are expected to guide lead optimization and the development of promising cyclin D/CDK axis inhibitors, offering novel avenues for cancer treatment.
Experimental and computational models to understand protein-ligand, metal-ligand and metal-DNA interactions pertinent to targeted cancer and other therapies
2024, European Journal of Medicinal Chemistry ReportsThe protein-ligand interactions play critical roles in targeted therapies including viral and cancer therapies. Hence in recent years several experimental and computational methods have been developed to address the mechanism of selectivity, swift binding, and enzyme functions. Furthermore big data, neural networks and artificial intelligence techniques are becoming increasingly important while combinatorial and graph theoretical methods are important arms of such techniques. Experimental methods such as isothermal titration calorimetry and surface plasmon resonance are used frequently to measure the binding affinity. Some of the computational methods used to examine the protein-ligand interactions are electrostatic calculations, molecular dynamics simulation, hybrid dynamics methods, etc., which shed light on structural stability, binding, protein functions etc. In this review we describe applications of a few selected experimental, computational and artificial intelligence tools with focus on graph theory to predict protein-ligand, metal-ligand interactions with implications in various types of malignancies and computational toxicology with focus on protein-heavy metal ion interactions and complexes of heavy metal ions with various ligands of biomedical relevance.
Computational investigation of turmeric phytochemicals targeting PTR1 enzyme of Leishmania species
2024, HeliyonIn this study, we used in silico techniques to identify available parasite treatments, representing a promising therapeutic avenue. Building upon our computational initiatives aimed at discovering natural inhibitors for various target enzymes from parasites causing neglected tropical diseases (NTDs), we present novel findings on three turmeric-derived phytochemicals as inhibitors of Leishmania pteridine reductase I (PTR1) through in silico methodologies. PTR1, a crucial enzyme in the unique folate metabolism of trypanosomatid parasites, holds established therapeutic significance. Employing MOE software, a molecular docking analysis assesses the efficacy of turmeric phytochemicals against Leishmania PTR1. Validation of the docking protocol is confirmed with an RMSD value of 2. Post-docking, compounds displaying notable interactions with critical residues and binding affinities ranging between −6 and −8 kcal/mol are selected for interaction pattern exploration. Testing twelve turmeric phytochemicals, including curcumin, zingiberene, curcumol, curcumenol, eugenol, bisdemethoxycurcumin, tetrahydrocurcumin, tryethylcurcumin, turmerones, turmerin, demethoxycurcumin, and turmeronols, revealed binding affinities ranging from −5.5 to −8 kcal/mol. Notably, curcumin, demethoxycurcumin, and bisdemethoxycurcumin exhibit binding affinities within −6.5 to −8 kcal/mol and establish substantial interactions with catalytic residues. These phytochemicals hold promise as lead structures for rational drug design targeting Leishmania spp. PTR in future applications. This work underscores the potential of these identified phytochemicals in the development of more effective inhibitors, demonstrating their relevance in addressing neglected tropical diseases caused by parasites.
Echinacea purpurea polysaccharide intervene in hepatocellular carcinoma via modulation of gut microbiota to inhibit TLR4/NF-κB pathway
2024, International Journal of Biological MacromoleculesEchinacea purpurea polysaccharide (EPP) exhibit various pharmacological activities, including immunomodulatory, anti-inflammatory, and anti-tumor effects. In this study, we investigated the potential mechanism of EPP intervention in hepatocellular carcinoma (HCC). The results demonstrated that EPP effectively mitigated liver injury caused by HCC, inhibited the proliferation of HCC, and induced apoptosis. Following EPP intervention, there was a significant increase in propionic acid and butyric acid-producing gut microbiota such as Coprococcus, Clostridium and Roseburia, leading to enhanced expression of intestinal tight junction proteins and the repair of the intestinal barrier. This controls lipopolysaccharide (LPS) leakage, which in turn inhibits the TLR4/NF-κB pathway and reduces the expression of inflammatory factors such as IL-6, as well as migration factors like MMP-2. Metabolomics revealed the downregulation of pyrimidine metabolism and nucleotide metabolism, along with the upregulation of butyrate metabolism in tumor cells. This study demonstrated that EPP effectively regulated LPS leakage by modulating gut microbes, and this modulation influenced the TLR4/NF-κB pathway, ultimately disrupting tumor cell survival induced by HCC in mice.
Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies
2024, International Journal of Biological MacromoleculesJanus kinase 2 (JAK2), one of the JAK isoforms participating in a JAK/STAT signaling cascade, has been considered a potential clinical target owing to its critical role in physiological processes involved in cell growth, survival, development, and differentiation of various cell types, especially immune and hematopoietic cells. Substantial studies have proven that the inhibition of this target could disrupt the JAK/STAT pathway and provide therapeutic outcomes for cancer, immune disorders, inflammation, and COVID-19. Herein, we performed docking-based virtual screening of 63 in-house furopyridine-based compounds and verified the first-round screened compounds by in vitro enzyme- and cell-based assays. By shedding light on the integration of both in silico and in vitro methods, we could elucidate two promising compounds. PD19 showed cytotoxic effects on human erythroblast cell lines (TF-1 and HEL) with IC50 values of 57.27 and 27.28 μM, respectively, while PD12 exhibited a cytotoxic effect on TF-1 with an IC50 value of 83.47 μM by suppressing JAK2/STAT5 autophosphorylation. In addition, all screened compounds were predicted to meet drug-like criteria based on Lipinski's rule of five, and none of the extreme toxicity features were found. Molecular dynamic simulations revealed that PD12 and PD19 could form stable complexes with JAK2 in an aqueous environment, and the van der Waals interactions were the main force driving the complex formation. Besides, all compounds sufficiently interacted with surrounding amino acids in all crucial regions, including glycine, catalytic, and activation loops. Altogether, PD12 and PD19 identified here could potentially be developed as novel therapeutic inhibitors disrupting the JAK/STAT pathway.
- f1
Corresponding author